La Jolla Pharmaceutical autoimmune, inflammation news
La Jolla will reduce headcount by an undisclosed number and evaluate strategic options, including a sale or wind down of the business after the company stopped the Phase III ASPEN trial of Riquent abetimus (LJP 394) to treat lupus nephritis. In February, an independent DMC determined that continuing the study would be futile based on an interim efficacy analysis. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN, Novato, Calif.) has an option to license worldwide, co-exclusive rights excluding the Asia-Pacific region to Riquent, a carrier plus 4 double-stranded oligonucleotides that bind to anti- dsDNA antibodies on B cells. La Jolla's remaining pipeline includes preclinical inhibitors of vascular adhesion protein-1 (VAP-1, SSAO) to treat inflammation. ...